SOURCE: Sunshine Biopharma Inc.

Sunshine Biopharma Inc.

June 19, 2013 08:00 ET

Sunshine Biopharma's Anticancer Drug Candidate, Adva-27a, Is Unaffected by the Recent Supreme Court Ruling on Patentability of Human Genes

MONTREAL--(Marketwired - Jun 19, 2013) - Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announces that its operations are unaffected by the recent Supreme Court ruling on patentability of Human Genes. Sunshine Biopharma's anticancer drug development program is not dependent on and does not utilize human genes. Sunshine Biopharma had previously reported that Adva-27a is capable of effectively killing aggressive or multidrug resistant cancer cells including Breast Cancer cells (MCF-7/MDR), Small-Cell Lung Cancer cells (H69AR), Uterine Sarcoma cells (MES-SA/Dx5), and Pancreatic Cancer cells (Panc-1).

"Sunshine Biopharma is not in the business of patenting human genes or copies thereof, such as cDNA. We patent small molecules for use as chemotherapeutics in the treatment of cancer," said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. 

About Sunshine Biopharma Inc.
Sunshine Biopharma is an early stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. Sunshine Biopharma recently announced that it has initiated IND-Enabling studies for its lead antitumor compound, Adva-27a, which is currently targeted for multidrug resistant cancer.

Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

Contact Information